+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmaceutical Manufacturing Market by Drug Type, Dosage Form, Manufacturing Stage, Manufacturing Technology, End Use - Global Forecast to 2030- Product Image
Pharmaceutical Manufacturing Market by Drug Type, Dosage Form, Manufacturing Stage, Manufacturing Technology, End Use - Global Forecast to 2030- Product Image
Sale

Pharmaceutical Manufacturing Market by Drug Type, Dosage Form, Manufacturing Stage, Manufacturing Technology, End Use - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5896347
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmaceutical Manufacturing Market grew from USD 672.44 billion in 2024 to USD 731.63 billion in 2025. It is expected to continue growing at a CAGR of 8.73%, reaching USD 1.11 trillion by 2030.

Setting the Scene for Emerging Pharmaceutical Manufacturing Trends

The pharmaceutical manufacturing sector stands at a pivotal moment, shaped by rapid technological advancements, evolving regulatory frameworks, and shifting global trade dynamics. As stakeholder expectations intensify around product quality, supply chain resilience, and cost efficiency, manufacturers must navigate increasingly complex challenges to remain competitive. The convergence of digital transformation with novel production techniques presents an unprecedented opportunity to reimagine traditional processes, driving both incremental improvements and groundbreaking innovation.

In this context, an authoritative understanding of market drivers and barriers is essential. From the emergence of biosimilar therapies to the growing emphasis on sustainability, decision makers require a clear roadmap to prioritize investments and align operational strategies with long-term objectives. This executive summary distills comprehensive research into concise, actionable insights, designed to inform leadership discussions and catalyze meaningful change across every stage of the manufacturing lifecycle. By establishing a solid analytical foundation, organizations can anticipate market shifts, optimize resource allocation, and deliver high-value therapies with greater speed and reliability.

Navigating the Transformative Shifts Reshaping Pharmaceutical Production

Over the past decade, pharmaceutical production has undergone a transformational shift, driven by digitalization, biotechnology innovations, and a heightened focus on patient-centric therapies. Advanced process analytics and real-time monitoring systems have redefined quality control, enabling continuous manufacturing approaches that reduce cycle times and enhance consistency. Concurrently, breakthroughs in personalized medicine and gene therapies have challenged conventional batch operations, demanding greater flexibility and precision across the production pipeline.

Regulatory bodies have responded with updated frameworks that encourage innovation while maintaining rigorous safety standards. Collaboration among manufacturers, technology providers, and academic institutions has accelerated the adoption of single-use systems and modular facilities, democratizing access to high-complexity manufacturing capabilities. As environmental sustainability becomes a board-level concern, companies are integrating green chemistry principles and energy-efficient equipment, underscoring a broader industry commitment to responsible production.

Assessing the Cumulative Impact of United States 2025 Tariffs on Supply Chains

The tariff adjustments enacted by the United States in 2025 have introduced significant cost pressures across raw material procurement and component sourcing. APIs and excipients imported from key regions now incur heightened duties, prompting manufacturers to reevaluate supplier networks and logistics strategies. The immediate consequence has been an uptick in landed costs, which compresses margins and compels a reassessment of pricing models throughout the value chain.

Supply chain managers are responding by diversifying procurement channels and exploring nearshoring alternatives to mitigate exposure to trade policy volatility. Strategic stockpiling of critical inputs has emerged as a temporary buffer against tariff-induced disruptions, while long-term solutions include forging partnerships with domestic producers. Despite these adjustments, compliance complexities have increased, requiring robust documentation and more sophisticated tariff classification processes. As companies refocus on operational resilience, those that implement agile sourcing frameworks will be best positioned to sustain competitive advantage amid evolving trade environments.

Illuminating Market Segmentation with Comprehensive Insights

A granular segmentation analysis reveals nuanced growth trajectories and operational imperatives across distinct market categories. In the realm of drug type, biosimilar products are gaining traction as patent expirations create opportunities for cost-effective therapeutic alternatives, while branded drugs continue to command premium pricing supported by robust clinical evidence. Simultaneously, generic drugs maintain a critical role in expanding access to essential medicines, driving volume-based efficiencies for high-demand treatments.

Exploring the domain of dosage forms highlights the sustained dominance of solid formats, where capsules, powders, and tablets serve as the backbone of mass-market distribution. However, liquid formulations such as emulsions, solutions, and suspensions are carving out niche applications in pediatric and ophthalmic care. Parenteral delivery methods are experiencing a surge, especially infusion systems and injectable formats; within this space, prefilled syringes and vials offer enhanced dose accuracy and patient convenience.

Production workflows are further delineated by manufacturing stage, spanning the upstream synthesis of active pharmaceutical ingredients into comprehensive formulation processes and culminating in precise packaging and labeling protocols. Technology-driven distinctions between batch manufacturing, continuous flow systems, and modular single-use platforms underscore the industry’s dual pursuit of flexibility and scale. Finally, end-use considerations bifurcate demand into animal health solutions, which prioritize robustness and cost containment, and human health therapies, where regulatory stringency and clinical efficacy are paramount.

Unlocking Regional Dynamics Driving Global Pharma Expansion

Regional forces are exerting powerful influence on investment strategies and capacity expansions. Across the Americas, a mature ecosystem of contract development and manufacturing organizations continues to foster innovation hubs, underpinned by robust IP protections and advanced infrastructure. In Europe, Middle East & Africa, regulatory harmonization initiatives and growing biotech clusters are attracting cross-border partnerships, even as individual markets balance cost pressures with healthcare accessibility goals. The Asia-Pacific region stands out for its rapid scaling of production capabilities, driven by government incentives in markets such as China, India, and Japan, and a burgeoning talent pool specializing in both small-molecule and biologics manufacturing.

These geographic distinctions are crucial for stakeholders mapping site selection, technology deployment, and distribution strategies. Supply chain agility, regulatory alignment, and market access considerations vary markedly across regions, requiring a tailored approach to logistics, quality assurance, and stakeholder engagement. By understanding the nuanced interplay of local policies, talent availability, and demand dynamics, manufacturers can optimize their global footprint and accelerate time to market.

Profiling Leading Players Shaping Industry Evolution

Leading players are redefining competitive landscapes through strategic investments, cross-sector alliances, and technology-centric roadmaps. Major biologics developers are scaling up high-volume production lines while integrating continuous bioprocessing to enhance yield consistency. Generics market incumbents are broadening portfolios to target complex formulations and biosimilar follow-ons, drawing on deep cost-optimization expertise to sustain margin growth. Contract manufacturing organizations are expanding modular facilities and single-use capabilities to serve a diverse set of clients, spanning small biotech ventures to established pharmaceutical giants.

Meanwhile, equipment and technology suppliers are intensifying R&D efforts around process analytical technology and automation, offering integrated solutions that streamline workflow orchestration from crude synthesis through aseptic filling. Ecosystem partnerships between software innovators and hardware manufacturers are creating end-to-end digital platforms, enabling real-time visibility, predictive maintenance, and advanced analytics. These competitive dynamics underscore the importance of agility, collaboration, and continuous innovation in capturing high-growth segments and delivering differentiated value propositions.

Strategic Recommendations to Empower Industry Leadership

Industry leaders must embrace strategic imperatives that balance operational efficiency with future-proof innovation. Advancing continuous manufacturing technologies can significantly reduce production cycles and waste generation, increasing throughput while enhancing quality control. Parallel investments in single-use systems bolster agility, enabling rapid scale-up for clinical and commercial launches without the constraints of fixed stainless-steel infrastructure.

Diversifying supply chains through regional nearshoring and dual-sourcing arrangements mitigates trade policy risks and secures access to critical materials. Cultivating a robust regulatory intelligence function ensures proactive alignment with evolving standards, streamlining approval timelines and minimizing compliance-related disruptions. Harnessing digital twins and predictive analytics facilitates scenario planning and capacity forecasting, empowering leadership to make data-driven investment decisions.

Finally, fostering a culture of cross-functional collaboration-spanning R&D, operations, quality assurance, and commercial teams-accelerates knowledge transfer and drives holistic performance improvements. By embedding sustainability metrics into core decision frameworks, organizations can meet escalating environmental, social, and governance expectations, reinforcing their social license to operate and strengthening stakeholder trust.

Rigorous Methodology Underpinning Our Insights

This analysis is underpinned by a rigorous research methodology integrating both primary and secondary sources. Primary insights were garnered through in-depth interviews with senior executives across pharmaceutical and biotechnology companies, as well as discussions with regulatory authorities and supply chain specialists. Secondary research encompassed a systematic review of peer-reviewed journals, patent databases, corporate disclosures, and trade publications to triangulate market trends and validate emerging themes.

Quantitative data points were aggregated from industry associations, customs and tariff filings, and validated press releases, ensuring an accurate reflection of trade flows, capacity expansions, and technology adoption rates. Qualitative assessments were conducted using a standardized framework to evaluate innovation pipelines, operational maturity, and strategic positioning. All findings were subjected to multiple layers of peer review by subject-matter experts, guaranteeing robustness and impartiality. The resulting insights offer a balanced, thoroughly vetted perspective designed to inform high-stakes decision-making across executive teams.

Driving Forward: Concluding Reflections on Manufacturing's Next Frontier

The pharmaceutical manufacturing landscape is poised for accelerated transformation as technological innovation converges with shifting policy paradigms and market demands. Organizations that adopt a proactive posture-investing in continuous and single-use manufacturing, diversifying sourcing, and fortifying regulatory intelligence-will secure sustainable competitive advantages. By internalizing the segmentation nuances, regional dynamics, and tariff implications outlined in this summary, leaders can align strategic initiatives with the most promising growth avenues.

Moving forward, the industry must remain agile, adapting rapidly to next-generation therapies, evolving patient expectations, and emergent trade policies. Collaboration across stakeholders-spanning academia, technology providers, contract partners, and health authorities-will catalyze breakthrough advancements and enable a more resilient, efficient supply chain. Ultimately, the collective pursuit of operational excellence, quality, and sustainability will define success in this new era of pharmaceutical manufacturing.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Biosimilars
    • Branded Drugs
    • Generic Drugs
  • Dosage Form
    • Liquid Dosage Forms
      • Emulsion
      • Solution
      • Suspension
    • Parenteral Dosage Forms
      • Infusion Forms
      • Injectable Forms
        • Prefilled Syringe
        • Vial
    • Solid Dosage Forms
      • Capsule
      • Powder
      • Tablet
  • Manufacturing Stage
    • API Manufacturing
    • Formulation Manufacturing
    • Packaging And Labelling
  • Manufacturing Technology
    • Batch Manufacturing
    • Continuous Manufacturing
    • Single-Use Technology
  • End Use
    • Animal Health
    • Human Health
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • AbbVie Inc.
  • Sanofi S.A.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmaceutical Manufacturing Market, by Drug Type
8.1. Introduction
8.2. Biosimilars
8.3. Branded Drugs
8.4. Generic Drugs
9. Pharmaceutical Manufacturing Market, by Dosage Form
9.1. Introduction
9.2. Liquid Dosage Forms
9.2.1. Emulsion
9.2.2. Solution
9.2.3. Suspension
9.3. Parenteral Dosage Forms
9.3.1. Infusion Forms
9.3.2. Injectable Forms
9.3.2.1. Prefilled Syringe
9.3.2.2. Vial
9.4. Solid Dosage Forms
9.4.1. Capsule
9.4.2. Powder
9.4.3. Tablet
10. Pharmaceutical Manufacturing Market, by Manufacturing Stage
10.1. Introduction
10.2. API Manufacturing
10.3. Formulation Manufacturing
10.4. Packaging and Labelling
11. Pharmaceutical Manufacturing Market, by Manufacturing Technology
11.1. Introduction
11.2. Batch Manufacturing
11.3. Continuous Manufacturing
11.4. Single-Use Technology
12. Pharmaceutical Manufacturing Market, by End Use
12.1. Introduction
12.2. Animal Health
12.3. Human Health
13. Americas Pharmaceutical Manufacturing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Pharmaceutical Manufacturing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Pharmaceutical Manufacturing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Roche Holding AG
16.3.3. Johnson & Johnson
16.3.4. Merck & Co., Inc.
16.3.5. Novartis AG
16.3.6. AbbVie Inc.
16.3.7. Sanofi S.A.
16.3.8. AstraZeneca plc
16.3.9. Eli Lilly and Company
16.3.10. Bristol-Myers Squibb Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY HUMAN HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 61. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 62. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 63. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 64. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 65. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 66. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 116. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 118. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 125. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 127. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 129. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 141. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 143. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 144. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 145. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 146. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 147. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 148. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 150. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 152. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 154. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 156. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 186. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 188. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 190. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 191. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 192. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 204. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 206. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 207. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 208. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 209. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 210. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 211. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 213. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 214. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 215. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 219. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 240. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 242. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 244. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 246. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 249. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 251. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 253. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 254. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 255. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. TURKEY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 267. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 268. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 269. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 275. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 276. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 277. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 279. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 280. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 281. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 282. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 283. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 304. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 305. CHINA PHARMACEUTICAL MANUFACTU

Companies Mentioned

The companies profiled in this Pharmaceutical Manufacturing market report include:
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • AbbVie Inc.
  • Sanofi S.A.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 731.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 1110 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pharmaceutical Manufacturing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Pharmaceutical Manufacturing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 130 Pages
  • Global
From
Pharmaceutical Continuous Manufacturing Market by Component, Technology Type, Formulations, End-user, Therapeutic Area, Applications - Global Forecast to 2030 - Product Image

Pharmaceutical Continuous Manufacturing Market by Component, Technology Type, Formulations, End-user, Therapeutic Area, Applications - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 225 Pages
  • Global
From
Topical Drugs Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Semi-Solid Formulations, Solid Formulations), Scale of Operation (Clinical), End-use (Pharmaceutical Companies), Region, with Growth Forecasts, 2025-2030 - Product Image

Topical Drugs Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Semi-Solid Formulations, Solid Formulations), Scale of Operation (Clinical), End-use (Pharmaceutical Companies), Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Oral Proteins & Peptides Market by Product Type, Formulation, Development Stage, Application, End-User - Global Forecast to 2030 - Product Image

Oral Proteins & Peptides Market by Product Type, Formulation, Development Stage, Application, End-User - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From

About the Pharmaceutical Manufacturing Market

The Pharmaceutical Manufacturing market is composed of companies that produce drugs and other pharmaceutical products. These products are used to treat and prevent diseases, as well as to improve the quality of life. Pharmaceutical manufacturers are responsible for the research, development, production, and distribution of these products. They must adhere to strict regulations and standards to ensure the safety and efficacy of their products. The Pharmaceutical Manufacturing market is highly competitive, with many large companies vying for market share. Some of the major players in the market include Pfizer, Merck, Johnson & Johnson, Novartis, and GlaxoSmithKline. These companies are involved in the research, development, production, and distribution of pharmaceutical products. They are also involved in the marketing and promotion of their products. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.